INSIGHTS

Articles & Insights.

Thought leadership on the legal, regulatory, and business issues shaping the healthcare industry.

REAL ISSUES.

PRACTICAL INSIGHTS.

AHEAD OF THE CURVE.

Telepsychiatry Providers Face a December 31 Deadline: Controlled-Substance Prescribing Rules Remain Uncertain

Telepsychiatry Providers Face a December 31 Deadline: Controlled-Substance Prescribing Rules Remain Uncertain

Telehealth companies have spent years building healthcare models around the ability to evaluate and treat patients remotely.

For psychiatric practices, ADHD treatment platforms, and behavioral health companies, controlled-substance prescribing is particularly important.

The federal regulatory framework supporting certain remote prescriptions is approaching another critical deadline.

The Drug Enforcement Administration’s fourth temporary extension permits qualifying telemedicine prescribing of Schedule II–V controlled substances without a prior in-person medical evaluation through December 31, 2026, subject to applicable requirements.

As of October 12, 2026, that remains the announced expiration date of the temporary extension. 

Why This Matters for Telepsychiatry

Many psychiatric practices prescribe medications that fall within the federal controlled-substance framework.

For example, treatment of certain ADHD conditions may involve Schedule II medications.

Other psychiatric and behavioral health treatments may involve medications in different controlled-substance schedules.

During the temporary federal flexibilities, qualifying providers can prescribe certain controlled medications through telemedicine without first conducting an in-person examination, provided they satisfy the applicable requirements.

Those flexibilities have enabled numerous telepsychiatry businesses to operate remotely.

The Temporary Extension Is Not a Permanent Solution

The DEA has repeatedly extended the temporary framework while developing longer-term regulations.

However, a temporary extension should not be confused with a permanent authorization.

Unless further federal action changes the framework, the expiration of the current extension could affect providers relying on its authority.

Some separate permanent telemedicine prescribing rules exist, including rules addressing certain buprenorphine treatment and Veterans Affairs circumstances. Those authorities have distinct requirements and should not be assumed to cover every telepsychiatry prescribing relationship. 

Telehealth Companies Should Evaluate Their Exposure

A psychiatric platform should determine how many of its patients receive controlled-substance prescriptions through encounters relying on the temporary federal flexibility.

The company should also evaluate whether its prescribing model depends on a particular provider-patient relationship, in-person evaluation exception, or other federal authorization.

Operational questions include whether patients can obtain appropriate in-person evaluations if necessary, whether the company has sufficient clinical personnel, and how treatment continuity would be maintained if the rules change.

State Law Still Matters

Federal telemedicine prescribing authority does not eliminate state requirements.

Providers must separately consider professional licensure, applicable scope-of-practice rules, state prescribing restrictions, controlled-substance registrations, prescription drug monitoring requirements, and telehealth standards.

For multi-state psychiatric companies, those requirements can create significant operational complexity.

A model that is workable for a provider treating patients in one state may require additional documentation or regulatory steps in another.

Contracts Should Anticipate Regulatory Changes

Healthcare platforms should review provider agreements, professional services agreements, technology contracts, and patient-facing documents.

If prescribing rules change, the organization needs a clear process for modifying services, transitioning patients, and allocating responsibilities.

Apex Health Law advises psychiatric practices, behavioral health organizations, telehealth companies, and MSOs regarding multi-state operations, provider relationships, prescribing requirements, and healthcare regulatory compliance.

This article is provided for general informational purposes only and does not constitute legal advice.

Regulatory reference: DEA Fourth Temporary Extension of Telemedicine Prescribing Flexibilities⁠

Share:

More Posts

Send A Message